GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corium International Inc (NAS:CORI) » Definitions » Equity-to-Asset

Corium International (Corium International) Equity-to-Asset : 0.22 (As of Jun. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Corium International Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Corium International's Total Stockholders Equity for the quarter that ended in Jun. 2018 was $24.89 Mil. Corium International's Total Assets for the quarter that ended in Jun. 2018 was $112.13 Mil. Therefore, Corium International's Equity to Asset Ratio for the quarter that ended in Jun. 2018 was 0.22.

The historical rank and industry rank for Corium International's Equity-to-Asset or its related term are showing as below:

CORI's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Corium International Equity-to-Asset Historical Data

The historical data trend for Corium International's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corium International Equity-to-Asset Chart

Corium International Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17
Equity-to-Asset
Get a 7-Day Free Trial -2.71 0.18 0.35 0.04 0.19

Corium International Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.19 0.06 0.30 0.22

Competitive Comparison of Corium International's Equity-to-Asset

For the Biotechnology subindustry, Corium International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corium International's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corium International's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Corium International's Equity-to-Asset falls into.



Corium International Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Corium International's Equity to Asset Ratio for the fiscal year that ended in Sep. 2017 is calculated as

Equity to Asset (A: Sep. 2017 )=Total Stockholders Equity/Total Assets
=16.212/84.851
=0.19

Corium International's Equity to Asset Ratio for the quarter that ended in Jun. 2018 is calculated as

Equity to Asset (Q: Jun. 2018 )=Total Stockholders Equity/Total Assets
=24.892/112.131
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corium International  (NAS:CORI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Corium International Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Corium International's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Corium International (Corium International) Business Description

Traded in Other Exchanges
N/A
Address
Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.
Executives
Essex Woodlands Health Ventures Fund Vii Lp 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Robert S Breuil officer: Chief Financial Officer 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Ronald W Eastman director, 10 percent owner 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Paul Goddard director ADOLOR CORPORATION, 700 PENNSYLVANIA DR., EXTON PA 19341
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Ivan P. Gergel director C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO CA 94158
Peter D Staple director, officer: President & CEO 863 C MITTEN ROAD, BURLINGAME CA 94010
Joseph J. Sarret officer: Chief Business Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Corium International (Corium International) Headlines

From GuruFocus

Corium Appoints Perry Sternberg as Chief Executive Officer

By Marketwired Marketwired 04-03-2019